{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:53:26Z","timestamp":1790121206433,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government","award":["NRF-2020M3A9G3080330"],"award-info":[{"award-number":["NRF-2020M3A9G3080330"]}]},{"name":"the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government","award":["NRF-2020M3A9G3080330"],"award-info":[{"award-number":["NRF-2020M3A9G3080330"]}]},{"name":"the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government","award":["NRF-2020M3A9G3080330"],"award-info":[{"award-number":["NRF-2020M3A9G3080330"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-03997-2","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T14:03:33Z","timestamp":1741442613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer"],"prefix":"10.1007","volume":"74","author":[{"given":"Manh-Cuong","family":"Vo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van-Tan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van-Dinh-Huan","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Joo","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Kyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Jae","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"issue":"2","key":"3997_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4046\/trd.2020.0134","volume":"84","author":"JG Lee","year":"2021","unstructured":"Lee JG, Kim HC, Choi CM (2021) Recent trends of lung cancer in Korea. Tuberc Respir Dis (Seoul) 84(2):89\u201395. https:\/\/doi.org\/10.4046\/trd.2020.0134","journal-title":"Tuberc Respir Dis (Seoul)"},{"issue":"6","key":"3997_CR2","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.annonc.2021.02.025","volume":"32","author":"J Remon","year":"2021","unstructured":"Remon J, Aldea M, Besse B, Planchard D, Reck M, Giaccone G, Soria JC (2021) Small cell lung cancer: a slightly less orphan disease after immunotherapy. Ann Oncol 32(6):698\u2013709. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.025","journal-title":"Ann Oncol"},{"issue":"1","key":"3997_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"MR Charles","year":"2021","unstructured":"Charles MR, Elisabeth B, Corinne FF, Julien S (2021) Small-cell lung cancer. Nat Rev Dis Primers 7(1):3. https:\/\/doi.org\/10.1038\/s41572-020-00235-0","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"3997_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"AMC Dingemans","year":"2021","unstructured":"Dingemans AMC, Fr\u00fch M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE et al (2021) Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(7):839\u2013853. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.207","journal-title":"Ann Oncol"},{"issue":"4","key":"3997_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41568-022-00544-4","volume":"23","author":"A van Weverwijk","year":"2023","unstructured":"van Weverwijk A, de Visser KE (2023) Mechanisms driving the immunoregulatory function of cancer cells. Nat Rev Cancer 23(4):193\u2013215. https:\/\/doi.org\/10.1038\/s41568-022-00544-4","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3997_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41368-020-0084-8","volume":"12","author":"Zi Mei","year":"2020","unstructured":"Mei Zi, Huang J, Qiao B, Lam A-Y (2020) Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int J Oral Sci 12(1):16. https:\/\/doi.org\/10.1038\/s41368-020-0084-8","journal-title":"Int J Oral Sci"},{"issue":"10","key":"3997_CR7","doi-asserted-by":"publisher","first-page":"8131","DOI":"10.1007\/s00432-023-04737-8","volume":"149","author":"A Kallingal","year":"2023","unstructured":"Kallingal A, Olszewski M, Maciejewska N, Brankiewicz W, Baginski M (2023) Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol 149(10):8131\u20138141. https:\/\/doi.org\/10.1007\/s00432-023-04737-8","journal-title":"J Cancer Res Clin Oncol"},{"issue":"23","key":"3997_CR8","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szczesna A et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa1809064","journal-title":"N Engl J Med"},{"issue":"10212","key":"3997_CR9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K et al (2019) Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. The Lancet 394(10212):1929\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6","journal-title":"The Lancet"},{"issue":"8","key":"3997_CR10","doi-asserted-by":"publisher","first-page":"BE01","DOI":"10.7860\/JCDR\/2017\/26748.10469","volume":"11","author":"Sh Preeti","year":"2017","unstructured":"Preeti Sh, Pradeep K, Rachna Sh (2017) Natural killer cells - their role in tumour immunosurveillance. J Clin Diagn Res 11(8):BE01\u2013BE05. https:\/\/doi.org\/10.7860\/JCDR\/2017\/26748.10469","journal-title":"J Clin Diagn Res"},{"issue":"3","key":"3997_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jtho.2022.11.008","volume":"18","author":"F Kristen","year":"2023","unstructured":"Kristen F, Lucas AH, Haiyan Q, Madeline D, Masafumi I, Dan Y, Duane HH, Anish T, Jeffrey S, Claudia P (2023) An interleukin-15 superagonist enables antitumor efficacy of natural killer cells against all molecular variants of SCLC. J Thorac Oncol 18(3):350\u2013368. https:\/\/doi.org\/10.1016\/j.jtho.2022.11.008","journal-title":"J Thorac Oncol"},{"issue":"9","key":"3997_CR12","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jtho.2020.05.008","volume":"15","author":"AB Sarah","year":"2020","unstructured":"Sarah AB, Jonas BH, Fernando SFG, Joseph C, Ariena K, Xueyi D, Jai R, Stephanie RH, Matthew ER, Melissa JD, Tracy LL, Louis I, Daniel S, Nicholas DH, Kate DS (2020) Harnessing natural killer immunity in metastatic SCLC. J Thorac Oncol 15(9):1507\u20131521. https:\/\/doi.org\/10.1016\/j.jtho.2020.05.008","journal-title":"J Thorac Oncol"},{"key":"3997_CR13","unstructured":"NCT03410368. NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer. ClinicalTrials.gov, 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03410368."},{"issue":"4","key":"3997_CR14","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1172\/JCI97611","volume":"128","author":"JC Peter","year":"2018","unstructured":"Peter JC, Jun C, Guoan C, David GB, Theodore JS, Venkateshwar GK (2018) Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. J Clin Invest 128(4):1384\u20131396. https:\/\/doi.org\/10.1172\/JCI97611","journal-title":"J Clin Invest"},{"key":"3997_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"J Xianjie","year":"2019","unstructured":"Xianjie J, Jie W, Xiangying D, Fang X, Junshang G, Bo X, Xu W, Jian M, Ming Z, Xiaoling L, Yong L, Guiyuan L, Wei X, Can G, Zhaoyang Z (2019) Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer 18:10. https:\/\/doi.org\/10.1186\/s12943-018-0928-4","journal-title":"Mol Cancer"},{"key":"3997_CR16","doi-asserted-by":"publisher","first-page":"633205","DOI":"10.3389\/fimmu.2021.633205","volume":"12","author":"Z Cristina","year":"2021","unstructured":"Cristina Z, Silke P (2021) Natural killer cell interactions with myeloid derived suppressor cells in the tumor microenvironment and implications for cancer immunotherapy. Front Immunol 12:633205. https:\/\/doi.org\/10.3389\/fimmu.2021.633205","journal-title":"Front Immunol"},{"issue":"2","key":"3997_CR17","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1002\/mco2.242","volume":"4","author":"C Xu","year":"2023","unstructured":"Xu C, Xia Y, Zhang BW, Drokow EK, Li HY, Xu S, Wang Z, Wang SY, Jin P, Fang T, Xiong XM (2023) Macrophages facilitate tumor cell PD-L1 expression via an IL-1\u03b2-centered loop to attenuate immune checkpoint blockade. MedComm. 4(2):e242. https:\/\/doi.org\/10.1002\/mco2.242","journal-title":"MedComm."},{"issue":"10","key":"3997_CR18","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1158\/2159-8290.CD-18-1259","volume":"9","author":"D Wenjuan","year":"2019","unstructured":"Wenjuan D, Xiaojin W, Shoubao M, Yufeng W, Ansel PN, Zheng Z, Jianying Z, Don MB, Kai H, Michael AC, Jianhua Y (2019) The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. Cancer Discov 9(10):1422\u20131437. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1259","journal-title":"Cancer Discov"},{"key":"3997_CR19","doi-asserted-by":"publisher","first-page":"101413","DOI":"10.1016\/j.tranon.2022.101413","volume":"20","author":"TH Chu","year":"2022","unstructured":"Chu TH (2022) MC VO, TJ Lakshmi, SY Ahn, MK, GY Song, DeH Yang, JS Ahn, HJ Kim, SH Jung, JJ Lee, Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma. Transl Oncol 20:101413. https:\/\/doi.org\/10.1016\/j.tranon.2022.101413","journal-title":"Transl Oncol"},{"issue":"1","key":"3997_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1182\/blood.V91.1.196","volume":"91","author":"AB Geldhof","year":"1998","unstructured":"Geldhof AB, Moser M, Lespagnard L, Thielemans K, Baetselier PD (1998) Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood 91(1):196\u2013206","journal-title":"Blood"},{"issue":"7","key":"3997_CR21","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.4049\/jimmunol.152.7.3361","volume":"152","author":"D Nandi","year":"1994","unstructured":"Nandi D, Gross J, Allison JP (1994) CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J Immunol 152(7):3361\u20133369","journal-title":"J Immunol"},{"issue":"8","key":"3997_CR22","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1158\/2326-6066","volume":"7","author":"S Emilio","year":"2019","unstructured":"Emilio S, Erin MOB, Jenna RK, Tamer BS, Bulent AA, Wei Xu et al (2019) Anti-CTLA-4 Activates intratumoral NK Cells and combined with IL15\/IL15R\u03b1 complexes enhances tumor control. Cancer Immunol Res 7(8):1371\u20131380. https:\/\/doi.org\/10.1158\/2326-6066","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"3997_CR23","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK (2016) Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44(5):989\u20131004. https:\/\/doi.org\/10.1016\/j.immuni.2016.05.001","journal-title":"Immunity"},{"key":"3997_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.imlet.2017.12.004","volume":"194","author":"A Brittoli","year":"2018","unstructured":"Brittoli A, Fallarini S, Zhang H, Pieters RJ, Lombardi G (2018) In vitro studies on galectin-3 in human natural killer cells. Immunol Lett 194:4\u201312. https:\/\/doi.org\/10.1016\/j.imlet.2017.12.004","journal-title":"Immunol Lett"},{"issue":"5","key":"3997_CR25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/2326-6066.CIR-13-0171","volume":"2","author":"IPD Silva","year":"2014","unstructured":"Silva IPD, Gallois A, Sonia JB, Shaukat K, Ana CA, Vijay KK, Iman O, Nina B (2014) Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res 2(5):410\u2013422. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0171","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"3997_CR26","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-16-1467","volume":"77","author":"RU Akshata","year":"2017","unstructured":"Akshata RU, David J, Megan H, Mukesh B, Andrea C, Lourdes E, Santiago S, Jonathan MI, Pierre PM, Vito Q (2017) Novel hybrid phenotype revealed in small cell lung cancer by a transcription factor network model that can explain tumor heterogeneity. Cancer Res 77(5):1063\u20131074. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1467","journal-title":"Cancer Res"},{"issue":"8","key":"3997_CR27","first-page":"3932","volume":"43","author":"K Yamaguchi","year":"1983","unstructured":"Yamaguchi K, Abe K, Kameya T, Adachi I, Taguchi S, Otsubo K, Yanaihara N (1983) Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. Cancer Res 43(8):3932\u20133939","journal-title":"Cancer Res"},{"issue":"8","key":"3997_CR28","first-page":"2136","volume":"54","author":"Y Miyake","year":"1994","unstructured":"Miyake Y, Kodama T, Yamaguchi K (1994) Pro-gastrin-releasing peptide(31\u201398) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 54(8):2136\u20132140","journal-title":"Cancer Res"},{"issue":"4A","key":"3997_CR29","first-page":"2673","volume":"19","author":"P Stieber","year":"1999","unstructured":"Stieber P, Dienemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K, Yamaguchi K (1999) Pro-gastrin-releasing peptide (ProGRP)\u2013a useful marker in small cell lung carcinomas. Anticancer Res 19(4A):2673\u20132678","journal-title":"Anticancer Res"},{"issue":"7","key":"3997_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.clinbiochem.2004.05.007","volume":"37","author":"R Molina","year":"2004","unstructured":"Molina R, Filella X, Aug\u00e9 JM (2004) ProGRP: a new biomarker for small cell lung cancer. Clin Biochem 37(7):505\u2013511. https:\/\/doi.org\/10.1016\/j.clinbiochem.2004.05.007","journal-title":"Clin Biochem"},{"key":"3997_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12272-022-01389-z","volume":"45","author":"HJ Kim","year":"2022","unstructured":"Kim HJ, Young J, Lee YM (2022) Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. Arch Pharm Res 45:401\u2013416. https:\/\/doi.org\/10.1007\/s12272-022-01389-z","journal-title":"Arch Pharm Res"},{"issue":"10","key":"3997_CR32","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu J, Hodgins J, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, Azimi CS, Scheer AK, Randolph HE, Thompson TW, Zhang L, Iannello A, Mathur N, Jardine KE, Kirn GA, Bell JC, McBurney MW, Raulet DH, Ardolino M (2018) Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J Clin Invest 128(10):4654\u20134668. https:\/\/doi.org\/10.1172\/JCI99317","journal-title":"J Clin Invest"},{"issue":"24","key":"3997_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omto.2021.11.016","volume":"29","author":"A Poggi","year":"2021","unstructured":"Poggi A, Zocchi MR (2021) Natural killer cells and immune-checkpoint inhibitor therapy: current knowledge and new challenges. Mol Ther Oncolytics 29(24):26\u201342. https:\/\/doi.org\/10.1016\/j.omto.2021.11.016","journal-title":"Mol Ther Oncolytics"},{"issue":"261\u2013269","key":"3997_CR34","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1038\/cmi.2008.32","volume":"5","author":"AA Khawaja","year":"2008","unstructured":"Khawaja AA, Manjunatha AM, Yufeng X, Jim X (2008) Intercellular trogocytosis plays an important role in modulation of immune responses. Cell Mol Immunol 5(261\u2013269):2008. https:\/\/doi.org\/10.1038\/cmi.2008.32","journal-title":"Cell Mol Immunol"},{"issue":"15","key":"3997_CR35","doi-asserted-by":"publisher","first-page":"eabj3286","DOI":"10.1126\/sciadv.abj3286","volume":"8","author":"MS Hasim","year":"2022","unstructured":"Hasim MS, Marotel M, Hodgins JJ, Vulpis E, Makinson OJ, Asif S, Shih H-Y, Scheer AK, MacMillan O, Alonso FG, Burke KP, Cook DP, Li R, Petrucci MT, Santoni A, Fallon PG, Sharpe AH, Scium\u00e8 G, Veillette A, Zingoni A, Gray DA, McCurdy A, Ardolino M (2022) When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer. Sci Adv 8(15):eabj3286. https:\/\/doi.org\/10.1126\/sciadv.abj3286","journal-title":"Sci Adv"},{"issue":"30","key":"3997_CR36","doi-asserted-by":"publisher","first-page":"e2023739118","DOI":"10.1073\/pnas.2023739118","volume":"118","author":"T Murat","year":"2021","unstructured":"Murat T, James BW, Motonao O, Shimon S (2021) Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. PNAS 118(30):e2023739118. https:\/\/doi.org\/10.1073\/pnas.2023739118","journal-title":"PNAS"},{"issue":"1","key":"3997_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3978\/j.issn.2218-6751.2016.01.01","volume":"5","author":"CS Jordi","year":"2016","unstructured":"Jordi CS, Alberto V, Rafael R (2016) Cancer stem cells in small cell lung cancer. Transl Lung Cancer Res. 5(1):16\u201325. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2016.01.01","journal-title":"Transl Lung Cancer Res."},{"issue":"2","key":"3997_CR38","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ccr.2010.12.021","volume":"19","author":"J Calbo","year":"2011","unstructured":"Calbo J, van Montfort E, Proost N, Ellen van Drunen H, Beverloo B, Meuwissen R, Berns A (2011) A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 19(2):244\u2013256. https:\/\/doi.org\/10.1016\/j.ccr.2010.12.021","journal-title":"Cancer Cell"},{"issue":"3","key":"3997_CR39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14712598.2017.1271874","volume":"17","author":"IL Jesus","year":"2017","unstructured":"Jesus IL, Steven KG, William JM, Robert JC (2017) Targeting cancer stem cells with natural killer cell immunotherapy. Expert Opin Biol Ther 17(3):313\u2013324","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"3997_CR40","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1080\/17512433.2017.1356717","volume":"10","author":"CS Fernando","year":"2017","unstructured":"Fernando CS, Charles MR (2017) Atezolizumab for the treatment of non-small cell lung cancer. Expert Rev Clin Pharmacol 10(9):935\u2013945. https:\/\/doi.org\/10.1080\/17512433.2017.1356717","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"9","key":"3997_CR41","doi-asserted-by":"publisher","first-page":"e1624128","DOI":"10.1080\/2162402X.2019.1624128","volume":"8","author":"N Mohan","year":"2019","unstructured":"Mohan N, Hosain S, Zhao J, Shen Yi, Luo X, Jiang J, Endo Y, Wen Jin Wu (2019) Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1 + triple negative breast cancer cells. OncoImmunology 8(9):e1624128. https:\/\/doi.org\/10.1080\/2162402X.2019.1624128","journal-title":"OncoImmunology"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03997-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-03997-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03997-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T09:38:10Z","timestamp":1743068290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-03997-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["3997"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-03997-2","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"143"}}